DAPA-MI (Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack) was the only other clinical trial to evaluate SGLT2 inhibitors among patients with acute MI, but it had limited enrollment of patients with kidney dysfunction, few HF events and did not assess kidney outcomes9. This evidence concerns the gene SLC5A2 and hydrops fetalis.